Related Experiment Video
Updated: Jul 1, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
GGT6 as a Prognostic Biomarker and Therapeutic Target in Melanoma Using an Information-theoretical Method
Yi-Fei Yang1, Yun Geng1, Hui Xu1
1Institute of Regenerative Medicine, and Department of Dermatology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, P.R. China.
Cancer Genomics & Proteomics
|June 29, 2026
Summary
High GGT6 gene expression indicates poor melanoma prognosis. Inhibiting gamma-glutamyl transferase (GGT) with DON suppressed melanoma cell viability and reduced glutathione levels, suggesting GGT as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Melanoma incidence is rising globally, posing a significant challenge due to treatment resistance and recurrence.
- Identifying prognostic biomarkers is crucial for early diagnosis, personalized treatment, and developing novel therapies for melanoma.
Purpose of the Study:
- To identify prognostic biomarkers for melanoma.
- To investigate the therapeutic potential of gamma-glutamyl transferase (GGT) inhibition in melanoma.
Main Methods:
- Analysis of melanoma datasets (GSE126076, TCGA) using information-theoretic and survival analyses.
- In vitro studies involving GGT inhibitor 6-diazo-5-oxo-L-norleucin (DON) treatment on melanoma cell lines (A375, A2058).
- Assessment of cell viability (CCK-8 assay) and intracellular glutathione (GSH) levels.
Main Results:
- GGT6 was identified as a prognostic gene, with high expression correlating with shorter disease-specific survival.
- DON treatment significantly reduced melanoma cell proliferation and viability in a dose-dependent manner.
- GGT inhibition led to decreased intracellular GSH levels in melanoma cells.
Conclusions:
- This study establishes GGT6 as a novel prognostic biomarker for melanoma.
- GGT inhibition demonstrates therapeutic potential by suppressing melanoma cell viability.
- GGT emerges as a promising therapeutic target for melanoma treatment.
